Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11611] to MYO1F
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Product nameAnti-MYO1F antibody [EPR11611]
See all MYO1F primary antibodies
DescriptionRabbit monoclonal [EPR11611] to MYO1F
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Recombinant fragment corresponding to Human MYO1F.
- Fetal lung and A673 lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab169535 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Predicted molecular weight: 125 kDa.|
FunctionMyosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails are presumed to bind to membranous compartments, which would be moved relative to actin filaments.
Sequence similaritiesContains 1 IQ domain.
Contains 1 myosin head-like domain.
Contains 1 SH3 domain.
- Information by UniProt
- Myo1f antibody
- MYO1F_HUMAN antibody
- Myosin ID antibody
ab169535 has been referenced in 1 publication.
- Sakane T et al. A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. Oncotarget 9:6993-7009 (2018). PubMed: 29467945